Answers are grounded in this paper and cite their sources.
statistic for this second meta-analysis was -73% which can be equated to zero. This indicated that the data were homogeneous or that there was no observed heterogeneity. Due to low heterogeneity, the fixed-effects model was used. Based on this meta-analysis, psilocybin seems to show symptom improvement in some psychiatric illnesses. The effectiveness of psilocybin microdosing and the use of psilocybin, in general, need to be studied further to determine the efficacy and safety of potential applications in psychiatry.
No takes yet. Share an insight, caveat, or question.
Irizarry et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: